Michael Makris

Emeritus Professor of Haemostasis and Thrombosis in Sheffield, UK. I tweet about thrombosis, hemophilia, COVID-19, medicine, NHS & AI. Opinions are my own.

[Pip Nicolson @PipNicolson]

Thank you @ProfMakris for your clear and concise commentary on our #PITT case in @BrJHaem.

Take home message: test anyone with the combination of thrombosis and thrombocytopenia for anti-PF4 antibodies (by ELISA) and have a low threshold for starting non-heparin anticoagulation

[Michael Makris @ProfMakris]

This is my last-ever post on X. Since Twitter changed to X, the platform has become toxic and full of misinformation and disinformation. In the future I will be posting on LinkedIn and BlueSky.

[Michael Makris @ProfMakris]

Today is #WorldHemophiliaDay and this year's theme is that women and girls bleed too. Despite the development of brilliant treatments to treat severe #hemophilia in primarily men, the diagnosis and treatment of women have not received as much attention.

[Thomas Reiser @TomReiser]

📅April 17 is World Hemophilia Day!
Women & girls w/bleeding disorders (#WGBD) remain underdiagnosed & underserved. 💡
But we can change this - through recognition, diagnosis, treatment, & care, the QoL of women & girls will improve!
#WHD2025
@wfhemophilia @isth

[ISTH @isth]

This #WorldHemophiliaDay, we’re spotlighting the overlooked history of women and hemophilia. Experts Paula James and Megan Chaigneau join the ISTH Pulse Podcast to share insights from their powerful narrative review in @JTHjournal

🎧Listen: https://t.co/tuhqlN4vZY #WHD2025

[Michael Makris @ProfMakris]

This is the press release about the new #hemophilia B gene therapy that has been approved in China. So there are now 3 approved gene therapies for hemophilia B, 2 in US/Europe approved by the FDA/EMA and 1 in China approved by the Chinese regulator. https://t.co/LDftlWarec

[Neil Blumberg @neilblumberg1]

@ProfMakris @BloodJournal @bloodinquiry This is true in the USA. Not used routinely in healthy young patients with coagulation disorders. Mostly in critically ill patients with rather dismal prognoses for what it’s worth. Costs are much higher and general consensus is risks of known blood borne pathogens low. Until not

[Michael Makris @ProfMakris]

Thank you for the copies of the paper on the UK Infected Blood Inquiry that was published in @BloodJournal. It is interesting to see the section on lessons learned. Despite the @bloodinquiry, the UK continues to use cryo and FFP without viral inactivation. #hemophilia

[Brian O Mahony @Brianhemophilia]

It is subsequently licenced by FDA , EMA or other major regulator. In this case, Governments might consider paying for PWH to travel there for treatment. Good to see possible competition in market, especially with Pfizer withdrawing their licenced FIX GT, Beqvez 2/2

[Brian O Mahony @Brianhemophilia]

I understand it may be priced close to 10% of the US price for Hemgenix or approximately US$300,000. They could faclitate people travelling to China for treatment. May appeal to some wealthy individuals but I doubt Governments in many countries will send PWH there unless 1/2

[Michael Makris @ProfMakris]

Any idea of the price of this, @Brianhemophilia? Presumably there is nothing to stop patients from traveling to China to have it. It is difficult to believe it will cost anything remotely close to Hemgenix.

[Brian O Mahony @Brianhemophilia]

Belief Biomed and Takeda China announce licencing by the National Medical Products Administration ( NMPA)in China of their BBM-H901 FIX Gene Therapy. Interested to see if they pursue licencing from FDA or EMA which could make it a more viable option in US or Europe

[Michael Makris @ProfMakris]

There is an article about the UK Infected Blood Inquiry in this week's issue of the journal Blood. Unfortunately it is behind a paywall, and I do not have access to it through our university library. If you have access to it, can you let me have a copy?

[Michael Makris @ProfMakris]

Article on Generative AI in medicine published today in @NEJM. It discusses the potential uses and risks. One issue you can be sure of, is that AI will be embedded in the everyday practice of medicine in the very near future, even more than today. https://t.co/KfiB9opK3G

[EAHAD @EAHADnews]

Join @HermansCedric and @ProfMakris in this E-learning Insight session as they share practical strategies and key considerations to help you navigate the world of scientific publishing. Learn how to write with purpose and make your research stand out.📺 https://t.co/O2kd7O3XwV

[Michael Makris @ProfMakris]

If you are a scientist who is not using AI yet, this article from today's @Nature journal will be of great help. Whether we like it or not AI will be everywhere very soon, just like the internet.

[Michael Makris @ProfMakris]

Everybody has an opinion about racism, but as the author of this book explains, the plural of anecdote is not data. This is a serious book looking at the scientific evidence around racism. It will not come as a surprise to read that racism is still in everything.

[RPTH @RPTHjournal]

Using AI in Scientific Research! 👩‍💻

This study by @DeepaArachchil1 compares 7 different AI models to predict VTE risk in Covid-19 patients.

Read more about it: https://t.co/ENk6UyDr26
#artificialintelligence #covid #thrombosis

[Simon Kuestenmacher @simongerman600]

Who cares about life expectancy?! Healthy life expectancy is what matters. Roughly speaking in richer countries you are healthy for longer. Costa Rica punches above its weight while the US ranks as a pathetic 71st.

Great chart by @rubenbmathisen.

[Michael Makris @ProfMakris]

Vaccination skeptics should have a look at this figure. It shows the impact of the introduction of RSV vaccination for patients aged 75-80 on hospital admissions in the UK. https://t.co/KZNvbkXyS8

[Michael Makris @ProfMakris]

Important paper: In patients with cancer and venous thrombosis, extended anticoagulation with low dose Apixaban is as good as full dose Apixaban in preventing thrombosis recurrence and is associated with less bleeding. https://t.co/J6SFRIky9Y